الفهرس 
ABSTRACTOnly 14 pages are availabe for public view
 |  | from | 103 |  |  |
| | | from | 103 | | |
Abstract
ABSTRACT
Ovulation induction remains a milestone in the treatment of women with anovulatory infertility clomiphene citrate (CC) is considered the first line treatment for induction of ovulation in women with polycystic ovary syndrome (PCOS) while it may be used for ovulation induction in unexplained infertility.
Aromatase inhibitors (AI) have been introduced as a new treatment option that could challenge CC for ovulation induction. A systematic review of the literature was conducted in order to highlight the efficacy and safety of AI in female infertility. Current data from randomized and non-randomized trials suggest that AI may have a role in ovulation induction regimens in PCOS patients as well as for ovarian stimulation, since they achieve comparable clinical pregnancy rates to CC.
This study was done on 150 pts 12of them had irregular visits so they are excluded and the study was done on 138pts divided into three groups (letrozol( 33pts),clomide(66pts) and control group received placebo.letrozol group recieved5mg from 2nd to6th day of the cycle while clomide group received 100mg in the same period of the cycle while control group advised to have regular intercourse. We observe the three groups regarding ovulation rate,endometrial thickness , serum estrogen , pregnancy rate we concluded that pregnancy rate in the three groups as follows (15.2%,6.1%,5.2%)letrozole , clomide and placebo consequatively with P value of(0.215) which is non significant but the endometrial thickness at day of ovulation was significantly thinner in CC group (8.04±1.4) compared to letrozole (9.46±1.2)and placebo(9.3±3.1) groups with P value of 0.001(S)..
Keywords
Letrazole Versus Clomiphen Citrate
Management Of Unexplained Infertility.